Study: Insulin payment strategy could reduce costs for insurers, patients

A new study adds to a growing body of literature suggesting that human insulins may result in similar clinical outcomes as higher cost insulin analogues for many patients with type 2 diabetes, according to a report last week in JAMA. The study looked at an initiative implemented by a Medicare Advantage plan to encourage members with diabetes to switch from insulin analogue to human insulin. The program was associated with a small increase in population-level HbA1C, but no significant change in rates of serious hypoglycemia or hyperglycemia. Human insulin use increased to 70 percent of insulin prescriptions over the three-year initiative, while overall expenditures for insulin decreased by more than 50 percent.
Related News Articles
Headline
The deadline for health delivery organizations to apply for the AHA’s 2026 Foster G. McGaw Prize is 1 p.m. ET May 6. The award honors organizations that…
Headline
A study published March 31 by the National Institutes of Health found that adults living in rural areas have worse cardiovascular health than those in urban…
Headline
Cigarette smoking by adults has dropped to its lowest level in 60 years, the Centers for Disease Control and Prevention reported today. Despite that, tobacco…
Headline
In this conversation, Mindy Estes, M.D., former CEO of Saint Luke's Health System and former AHA board chair, and Roxanna Gapstur, R.N., CEO of WellSpan Health…
Headline
A case study by the AHA's Community Health Improvement network explains how Children’s Mercy Kansas City created a new model to coordinate its community…
Chairperson's File
Trust — in one another, in our field, and in our communities — is so important to what we do. Everyone should know that our hospitals and health systems are a…